Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -30,881 | -37,340 | -41,301 | -20,699 | -16,757 |
| Depreciation Amortization | N/A | N/A | N/A | N/A | 282 |
| Income taxes - deferred | N/A | N/A | N/A | -239 | -23 |
| Accounts payable and accrued liabilities | -2,139 | 2,301 | 1,213 | -2,513 | -836 |
| Other Working Capital | -6,646 | 3,345 | 5,641 | -8,560 | 5,590 |
| Other Operating Activity | 4,264 | 284 | 10,638 | 5,990 | 1,327 |
| Operating Cash Flow | $-35,402 | $-31,410 | $-23,809 | $-26,021 | $-10,417 |
| Cash Flows From Investing Activities | |||||
| Purchase Sale Intangibles | 0 | -5,500 | -4,500 | N/A | N/A |
| Other Investing Activity | 0 | -5,500 | -4,500 | 0 | 0 |
| Investing Cash Flow | $0 | $-5,500 | $-4,500 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 46,822 | 22,346 | 24,079 | 12,074 | 38,134 |
| Other Financing Activity | -64 | -31 | 0 | 0 | 308 |
| Financing Cash Flow | $46,758 | $22,315 | $24,079 | $12,074 | $38,442 |
| Beginning Cash Position | 2,630 | 17,225 | 21,455 | 35,402 | 7,377 |
| End Cash Position | 13,986 | 2,630 | 17,225 | 21,455 | 35,402 |
| Net Cash Flow | $11,356 | $-14,595 | $-4,230 | $-13,947 | $28,025 |
| Free Cash Flow | |||||
| Operating Cash Flow | -35,402 | -31,410 | -23,809 | -26,021 | -10,417 |
| Free Cash Flow | -35,402 | -31,410 | -23,809 | -26,021 | -10,417 |